新型口服抗凝药物治疗左心室血栓有效性的研究进展  

Research progress on the efficacy of novel oral anticoagulant for left ventricular thrombus

作　　者：张育大 杨芳[1,2] 尹念佩 杨颖[1,2] ZHANG Yuda;YANG Fang;YIN Nianpei;YANG Ying(Clinical Medical College,North Sichuan Medical College,Nanchong,Sichuan 637000,P.R.China;Department of Cardiology,Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan 637000,P.R.China)

机构地区：[1]川北医学院临床医学院,四川南充637000 [2]川北医学院附属医院心血管内科,四川南充637000

出　　处：《华西医学》2025年第4期640-644,共5页West China Medical Journal

摘　　要：左心室血栓(left ventricular thrombus,LVT)是心肌梗死及心力衰竭等心脏疾病的常见并发症。维生素K拮抗剂(vitamin K antagonist,VKA)是目前治疗LVT的主要方法,但其服用期间需要频繁监测凝血指标,可能导致患者依从性差。而新型口服抗凝药物(novel oral anticoagulant,NOAC)易于给药,无需监测国际标准化比值或饮食限制,随着NOAC的发展,未来VKA治疗LVT的地位可能被逐步取代。该文对近年来NOAC与VKA治疗LVT的疗效对比作一综述,以期为临床使用NOAC治疗LVT提供新的思路。Left ventricular thrombus(LVT)is a common complication of heart diseases such as myocardial infarction and heart failure.Vitamin K antagonist(VKA)is currently the main method for LVT,but its use requires frequent monitoring of coagulation indicators,which may lead to poor patient compliance.The novel oral anticoagulant(NOAC)is easy to administer and does not require monitoring of international normalized ratio or dietary restrictions.With the development of NOAC,the position of VKA for LVT may gradually be replaced in the future.This article provides a review of the comparative efficacy of NOAC and VKA for LVT in recent years,in order to provide new ideas for the clinical use of NOAC for LVT.

关 键 词：新型口服抗凝药物 左心室血栓 维生素K拮抗剂 抗凝治疗 

分 类 号：R541.4[医药卫生—心血管疾病]